Although anti-CTLA-4 therapy has brought benefits in clinical trials of melanoma, refractory mCRC, hepatocellular carcinoma, and malignant mesothelioma, no improvement was observed in terms of overall survival (OS) in patients with metastatic castration-resistant prostate cancer (30). This evidence concerns the gene CTLA4 and melanoma.